Furthermore, a real-world cohort study evaluating pomalidomide-based regimens in RRMM patients with chronic kidney disease confirmed comparable renal response rates (approximately 50%) in both moderate and severe chronic kidney disease groups, reinforcing the renal safety of pomalidomide when combined with anti-CD38 therapy.74 The gene discussed is CD38; the disease is chronic kidney disease.